Company Overview and News

55
Medical Device Firms in Focus on Expanded R&D Scope: 5 Picks

2018-06-26 zacks
The U.S. Medical Device industry trend in 2018 is reflective of extensive discovery and innovation in the life sciences industry over the past few years.
STE VAR SYK IDXX CERN ISRG ABMD ROSA

166
MedTech Overcomes Policy Hurdles, Long-Term Prospects Bright

2018-06-16 zacks
With the suspension of the controversial 2.3% medical device tax for another two years, the medical device industry is currently riding high on optimism. AdvaMed, the medical device industry’s lobbying group, which strongly advocated for this relief, noted that the tax repeal will provide a huge impetus to the companies to channelize their turnovers into strategic consolidations, research and developments and also help in creating new job opportunities.
IFK TGTX NXTM SRXTY BAX OSUR 1302 BSX SYK INSY CAH SRX SXMDF IFX ISRG HSIC 0165 MDT EGRX FTV JNJ SRDX ABMD ROSA

78
The Zacks Analyst Blog Highlights: Cerner, AmerisourceBergen, Fresenius and Olympus

2018-03-21 zacks
Chicago, IL – March 21, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Cerner Corporation (CERN - Free Report) , AmerisourceBergen Corporation (ABC - Free Report) , Fresenius Medical Care (FMS - Free Report) and Olympus Corp.
OCPNY MS.PRE NXTM MS.PRF ABCO MS.PRG MS.PRA CVS ABC MS.PRI MS.PRK CERN MS ROSA

48
Goldman Sachs Backs Emerging Markets: MedTech Stocks in Focus

2018-03-20 zacks
Emerging market investment has taken a backseat of late, thanks to the nonstop blows to the economy. The lingering geopolitical tension in Gulf, debt and policy related hazards in Latin America or the missile tests in North Korea have led stock investors to reconsider their outlay in these markets, earlier proclaimed to offer better growth opportunities than the United States. Going by the MSCI Emerging Markets Index, the last five-year annualized growth rate was just 5.
IFK IFX BSX JNJ MCFT ROSA MDT

67
3 Favorable Trends Dispelling Tax-Repeal Worries in MedTech

2018-03-20 zacks
The tax-repeal saga has been dominating the headlines of the U.S. MedTech industry since the last couple of months.
ABC OCPNY CERN NXTM ABCO MCFT ROSA CVS

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to EPA:ROSA / MEDTECH on message board site Silicon Investor.

Petition to Ban *ROSARIO* from SI The *ROSARIO* Hall of fame.